Aortic stenosis: A general overview of clinical, pathophysiological and therapeutic aspects

Expert Review of Cardiovascular Therapy

Volumn 11, Issue 2, 2013, Pages 239-250

  Akerström, Finn ^a,b   Barderas, Maria G ^b   Rodríguez Padial, Luis ^a,b  

^a HOSPITAL VIRGEN DE LA SALUD   (Spain)

^b HOSPITAL NACIONAL DE PARAPLÉJICOS   (Spain)

Author keywords

angiotensin converting enzyme inhibitors; aortic stenosis; aortic valve; biomarkers; pathogenesis; pathophysiology; proteomics; statins

Indexed keywords

ATORVASTATIN; BIOLOGICAL MARKER; EZETIMIBE; ROSUVASTATIN; SIMVASTATIN;

AORTA STENOSIS; AORTA VALVE STENOSIS; ATHEROSCLEROSIS; CALCIFIC AORTIC VALVE DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE COURSE; HEART VALVE REPLACEMENT; HUMAN; LIPID STORAGE; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PREVALENCE; PROTEOMICS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANIMALS; AORTIC VALVE; AORTIC VALVE STENOSIS; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; HUMANS; LIPID METABOLISM; VASCULAR CALCIFICATION;

EID: 84873921778     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.12.171     Document Type: Review

References (90)

1. Maganti K, Rigolin VH, Sarano ME, Bonow RO. Valvular heart disease: diagnosis and management. Mayo Clin. Proc. 85(5), 483-500 (2010).
2. Supino PG, Borer JS, Preibisz J, Bornstein A. The epidemiology of valvular heart disease: a growing public health problem. Heart Fail. Clin. 2(4), 379-393 (2006).
3. Rajamannan NM, Evans FJ, Aikawa E et al. Calcific aortic valve disease: not simply a degenerative process: a review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: calcific aortic valve disease -2011 update. Circulation 124(16), 1783-1791 (2011).
4. Libby P, Braunwald E. Braunwald's Heart Disease: a Textbook of Cardiovascular Medicine 8th edition. Saunders/Elsevier, Philadelphia, PA, USA (2008).
5. Beppu S, Suzuki S, Matsuda H, Ohmori F, Nagata S, Miyatake K. Rapidity of progression of aortic stenosis in patients with congenital bicuspid aortic valves. Am. J. Cardiol. 71(4), 322-327 (1993).
6. Tobin JR Jr, Rahimtoola SH, Blundell PE, Swan HJ. Percentage of left ventricular stroke work loss. A simple hemodynamic concept for estimation of severity in valvular aortic stenosis. Circulation 35(5), 868-879 (1967).
7. Jonasson R, Jonsson B, Nordlander R, Orinius E, Szamosi A. Rate of progression of severity of valvular aortic stenosis. Acta Med. Scand. 213(1), 51-54 (1983).
8. American College of Cardiology/American Heart Association Task Force on Practice Guidlines, Society of Cardiovascular A, Society for Cardiovascular A et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 114(5), e84-e231 (2006).
9. Vahanian A, Baumgartner H, Bax J et al.; Task Force on the Management of Valvular Hearth Disease of the European Society of Cardiology; ESC Committee for Practice Guidelines. Guidelines on the management of valvular heart disease: The Task Force on the Management of valvular heart disease of the European Society of Cardiology. Eur. Heart J. 28(2), 230-268 (2007).
10. Pantely G, Morton M, Rahimtoola SH. Effects of successful, uncomplicated valve replacement on ventricular hypertrophy, volume, and performance in aortic stenosis and in aortic incompetence. J. Thorac. Cardiovasc. Surg. 75(3), 383-391 (1978).
11. Pellikka PA, Nishimura RA, Bailey KR, Tajik AJ. The natural history of adults with asymptomatic, hemodynamically significant aortic stenosis. J. Am. Coll. Cardiol. 15(5), 1012-1017 (1990).
12. Pellikka PA, Sarano ME, Nishimura RA et al. Outcome of 622 adults with asymptomatic, hemodynamically significant aortic stenosis during prolonged follow-up. Circulation 111(24), 3290-3295 (2005).
13. Brown ML, Pellikka PA, Schaff HV et al. The benefits of early valve replacement in asymptomatic patients with severe aortic stenosis. J. Thorac. Cardiovasc. Surg. 135(2), 308-315 (2008).
14. Vahanian A, Alfieri O, Andreotti F et al. Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur. J. Cardiothorac. Surg. 42(4), S1-S44 (2012).
15. Blevins TL, Carroll JL, Raza AM, Grande-Allen KJ. Phenotypic characterization of isolated valvular interstitial cell subpopulations. J. Heart Valve Dis. 15(6), 815-822 (2006).
16. Liu AC, Joag VR, Gotlieb AI. The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology. Am. J. Pathol. 171(5), 1407-1418 (2007).
17. Chen JH, Yip CY, Sone ED, Simmons CA. Identification and characterization of aortic valve mesenchymal progenitor cells with robust osteogenic calcification potential. Am. J. Pathol. 174(3), 1109-1119 (2009).
18. Davies PF, Passerini AG, Simmons CA. Aortic valve: turning over a new leaf(let) in endothelial phenotypic heterogeneity. Arterioscler. Thromb. Vasc. Biol. 24(8), 1331-1333 (2004).
19. Simmons CA, Grant GR, Manduchi E, Davies PF. Spatial heterogeneity of endothelial phenotypes correlates with sidespecific vulnerability to calcification in normal porcine aortic valves. Circ. Res. 96(7), 792-799 (2005).
20. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O'Brien KD. Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 90(2), 844-853 (1994).
21. Stewart BF, Siscovick D, Lind BK et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J. Am. Coll. Cardiol. 29(3), 630-634 (1997).
22. Lindroos M, Kupari M, Heikkilä J, Tilvis R. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J. Am. Coll. Cardiol. 21(5), 1220-1225 (1993).
23. Balachandran K, Sucosky P, Jo H, Yoganathan AP. Elevated cyclic stretch alters matrix remodeling in aortic valve cusps: implications for degenerative aortic valve disease. Am. J. Physiol. Heart Circ. Physiol. 296(3), H756-H764 (2009).
24. Balachandran K, Sucosky P, Jo H, Yoganathan AP. Elevated cyclic stretch induces aortic valve calcification in a bone morphogenic protein-dependent manner. Am. J. Pathol. 177(1), 49-57 (2010).
25. Metzler SA, Pregonero CA, Butcher JT, Burgess SC, Warnock JN. Cyclic strain regulates pro-inflammatory protein expression in porcine aortic valve endothelial cells. J. Heart Valve Dis. 17(5), 571-577; discussion 578 (2008).
26. Xing Y, Warnock JN, He Z, Hilbert SL, Yoganathan AP. Cyclic pressure affects the biological properties of porcine aortic valve leaflets in a magnitude and frequency dependent manner. Ann. Biomed. Eng. 32(11), 1461-1470 (2004).
27. Olsson M, Thyberg J, Nilsson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler. Thromb. Vasc. Biol. 19(5), 1218-1222 (1999).
28. Olsson M, Dalsgaard CJ, Haegerstrand A, Rosenqvist M, Rydén L, Nilsson J. Accumulation of T lymphocytes and expression of interleukin-2 receptors in nonrheumatic stenotic aortic valves. J. Am. Coll. Cardiol. 23(5), 1162-1170 (1994).
29. Jian B, Narula N, Li QY, Mohler ER 3rd, Levy RJ. Progression of aortic valve stenosis: TGF-β-1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. Ann. Thorac. Surg. 75(2), 457-465; discussion 465 (2003).
30. Kaden JJ, Dempfle CE, Grobholz R et al. Interleukin-1 β promotes matrix metalloproteinase expression and cell proliferation in calcific aortic valve stenosis. Atherosclerosis 170(2), 205-211 (2003).
31. Kaden JJ, Dempfle CE, Grobholz R et al. Inflammatory regulation of extracellular matrix remodeling in calcific aortic valve stenosis. Cardiovasc. Pathol. 14(2), 80-87 (2005).
32. Miller JD, Weiss RM, Heistad DD. Calcific aortic valve stenosis: methods, models, and mechanisms. Circ. Res. 108(11), 1392-1412 (2011).
33. Miller JD, Chu Y, Brooks RM, Richenbacher WE, Peña-Silva R, Heistad DD. Dysregulation of antioxidant mechanisms contributes to increased oxidative stress in calcific aortic valvular stenosis in humans. J. Am. Coll. Cardiol. 52(10), 843-850 (2008).
34. Miller JD, Weiss RM, Serrano KM et al. Lowering plasma cholesterol levels halts progression of aortic valve disease in mice. Circulation 119(20), 2693-2701 (2009).
35. Cucoranu I, Clempus R, Dikalova A et al. NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ. Res. 97(9), 900-907 (2005).
36. O'Brien KD, Shavelle DM, Caulfield MT et al. Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation 106(17), 2224-2230 (2002).
37. Helske S, Lindstedt KA, Laine M et al. Induction of local angiotensin II-producing systems in stenotic aortic valves. J. Am. Coll. Cardiol. 44(9), 1859-1866 (2004).
38. Yamamoto K, Yamamoto H, Yoshida K et al. Prognostic factors for progression of early-and late-stage calcific aortic valve disease in Japanese: the Japanese Aortic Stenosis Study (JASS) retrospective analysis. Hypertens. Res. 33(3), 269-274 (2010).
39. Rajamannan NM. Calcific aortic stenosis: lessons learned from experimental and clinical studies. Arterioscler. Thromb. Vasc. Biol. 29(2), 162-168 (2009).
40. Mohler ER 3rd, Gannon F, Reynolds C, Zimmerman R, Keane MG, Kaplan FS. Bone formation and inflammation in cardiac valves. Circulation 103(11), 1522-1528 (2001).
41. Rajamannan NM, Subramaniam M, Rickard D et al. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 107(17), 2181-2184 (2003).
42. Shen M, Marie P, Farge D et al. Osteopontin is associated with bioprosthetic heart valve calcification in humans. C. R. Acad. Sci. III 320(1), 49-57 (1997).
43. Yip CY, Chen JH, Zhao R, Simmons CA. Calcification by valve interstitial cells is regulated by the stiffness of the extracellular matrix. Arterioscler. Thromb. Vasc. Biol. 29(6), 936-942 (2009).
44. Paranya G, Vineberg S, Dvorin E et al. Aortic valve endothelial cells undergo transforming growth factor-beta-mediated and non-transforming growth factor-β-mediated transdifferentiation in vitro. Am. J. Pathol. 159(4), 1335-1343 (2001).
45. Tanaka K, Sata M, Fukuda D et al. Age-associated aortic stenosis in apolipoprotein E-deficient mice. J. Am. Coll. Cardiol. 46(1), 134-141 (2005).
46. Gu X, Masters KS. Role of the MAPK/ERK pathway in valvular interstitial cell calcification. Am. J. Physiol. Heart Circ. Physiol. 296(6), H1748-H1757 (2009).
47. Osman L, Yacoub MH, Latif N, Amrani M, Chester AH. Role of human valve interstitial cells in valve calcification and their response to atorvastatin. Circulation 114(1 Suppl.), I547-I552 (2006).
48. Monzack EL, Gu X, Masters KS. Efficacy of simvastatin treatment of valvular interstitial cells varies with the extracellular environment. Arterioscler. Thromb. Vasc. Biol. 29(2), 246-253 (2009).
49. Hjortnaes J, Butcher J, Figueiredo JL et al. Arterial and aortic valve calcification inversely correlates with osteoporotic bone remodelling: a role for inflammation. Eur. Heart J. 31(16), 1975-1984 (2010).
50. Ortlepp JR, Pillich M, Schmitz F et al. Lower serum calcium levels are associated with greater calcium hydroxyapatite deposition in native aortic valves of male patients with severe calcific aortic stenosis. J. Heart Valve Dis. 15(4), 502-508 (2006).
51. Maher ER, Young G, Smyth-Walsh B, Pugh S, Curtis Jr. Aortic and mitral valve calcification in patients with end-stage renal disease. Lancet 2(8564), 875-877 (1987).
52. Linhartová K, Veselka J, Sterbáková G, Racek J, Topolcan O, Cerbák R. Parathyroid hormone and vitamin D levels are independently associated with calcific aortic stenosis. Circ. J. 72(2), 245-250 (2008).
53. Banks LM, Lees B, MacSweeney JE, Stevenson JC. Effect of degenerative spinal and aortic calcification on bone density measurements in post-menopausal women: links between osteoporosis and cardiovascular disease? Eur. J. Clin. Invest. 24(12), 813-817 (1994).
54. Aksoy Y, Yagmur C, Tekin GO et al. Aortic valve calcification: association with bone mineral density and cardiovascular risk factors. Coron. Artery Dis. 16(6), 379-383 (2005).
55. Persy V, D'Haese P. Vascular calcification and bone disease: the calcification paradox. Trends Mol. Med. 15(9), 405-416 (2009).
56. Huntington K, Hunter AG, Chan KL. A prospective study to assess the frequency of familial clustering of congenital bicuspid aortic valve. J. Am. Coll. Cardiol. 30(7), 1809-1812 (1997).
57. Le Gal G, Bertault V, Bezon E, Cornily JC, Barra JA, Blanc JJ. Heterogeneous geographic distribution of patients with aortic valve stenosis: arguments for new aetiological hypothesis. Heart 91(2), 247-249 (2005).
58. Ortlepp JR, Hoffmann R, Ohme F, Lauscher J, Bleckmann F, Hanrath P. The vitamin D receptor genotype predisposes to the development of calcific aortic valve stenosis. Heart 85(6), 635-638 (2001).
59. Ferrari S, Rizzoli R, Chevalley T, Slosman D, Eisman JA, Bonjour JP. Vitamin-Dreceptor-gene polymorphisms and change in lumbar-spine bone mineral density. Lancet 345(8947), 423-424 (1995).
60. Garg V, Muth AN, Ransom JF et al. Mutations in NOTCH1 cause aortic valve disease. Nature 437(7056), 270-274 (2005).
61. Nordström P, Glader CA, Dahlén G et al. Oestrogen receptor α gene polymorphism is related to aortic valve sclerosis in postmenopausal women. J. Intern. Med. 254(2), 140-146 (2003).
62. Novaro GM, Sachar R, Pearce GL, Sprecher DL, Griffin BP. Association between apolipoprotein E alleles and calcific valvular heart disease. Circulation 108(15), 1804-1808 (2003).
63. Kawaguchi A, Miyatake K, Yutani C et al. Characteristic cardiovascular manifestation in homozygous and heterozygous familial hypercholesterolemia. Am. Heart J. 137(3), 410-418 (1999).
64. Weiss RM, Ohashi M, Miller JD, Young SG, Heistad DD. Calcific aortic valve stenosis in old hypercholesterolemic mice. Circulation 114(19), 2065-2069 (2006).
65. Rajamannan NM, Subramaniam M, Caira F, Stock SR, Spelsberg TC. Atorvastatin inhibits hypercholesterolemiainduced calcification in the aortic valves via the Lrp5 receptor pathway. Circulation 112(9 Suppl.), I229-I234 (2005).
66. Rajamannan NM, Subramaniam M, Springett M et al. Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation 105(22), 2660-2665 (2002).
67. Rajamannan NM, Subramaniam M, Stock SR et al. Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve. Heart 91(6), 806-810 (2005).
68. Rosenhek R, Rader F, Loho N et al. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation 110(10), 1291-1295 (2004).
69. Cowell SJ, Newby DE, Prescott RJ et al.; Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N. Engl. J. Med. 352(23), 2389-2397 (2005).
70. Rossebø AB, Pedersen TR, Boman K et al.; SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N. Engl. J. Med. 359(13), 1343-1356 (2008).
71. Chan KL, Teo K, Dumesnil JG, Ni A, Tam J; ASTRONOMER Investigators. Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation 121(2), 306-314 (2010).
72. Moura LM, Ramos SF, Zamorano JL et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J. Am. Coll. Cardiol. 49(5), 554-561 (2007).
73. Helske S, Otto CM. Lipid lowering in aortic stenosis: still some light at the end of the tunnel? Circulation 119(20), 2653-2655 (2009).
74. Antonini-Canterin F, Hîrsu M, Popescu BA et al. Stage-related effect of statin treatment on the progression of aortic valve sclerosis and stenosis. Am. J. Cardiol. 102(6), 738-742 (2008).
75. Reiner Z, Catapano AL, De Backer G et al. European Association for Cardiovascular P, Rehabilitation, ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur. Heart J. 32(14), 1769-1818 (2011).
76. Arishiro K, Hoshiga M, Negoro N et al. Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterolemic rabbits. J. Am. Coll. Cardiol. 49(13), 1482-1489 (2007).
77. Ngo DT, Stafford I, Sverdlov AL et al. Ramipril retards development of aortic valve stenosis in a rabbit model: mechanistic considerations. Br. J. Pharmacol. 162(3), 722-732 (2011).
78. O'Brien KD, Probstfield JL, Caulfield MT et al. Angiotensin-converting enzyme inhibitors and change in aortic valve calcium. Arch. Intern. Med. 165(8), 858-862 (2005).
79. Mayr M, Mayr U, Chung YL, Yin X, Griffiths JR, Xu Q. Vascular proteomics: linking proteomic and metabolomic changes. Proteomics 4(12), 3751-3761 (2004).
80. Marian AJ, Nambi V. Biomarkers of cardiac disease. Expert Rev. Mol. Diagn. 4(6), 805-820 (2004).
81. Pandey A, Mann M. Proteomics to study genes and genomes. Nature 405(6788), 837-846 (2000).
82. Mebazaa A, Vanpoucke G, Thomas G et al. Unbiased plasma proteomics for novel diagnostic biomarkers in cardiovascular disease: identification of quiescin Q6 as a candidate biomarker of acutely decompensated heart failure. Eur. Heart J. 33(18), 2317-2324 (2012).
83. Martín-Rojas T, Gil-Dones F, Lopez-Almodovar LF, Padial LR, Vivanco F, Barderas MG. Proteomic profile of human aortic stenosis: insights into the degenerative process. J. Proteome Res. 11(3), 1537-1550 (2012).
84. Yang Y, Trent MB, He N et al. Glutathione-S-transferase A4-4 modulates oxidative stress in endothelium: possible role in human atherosclerosis. Atherosclerosis 173(2), 211-221 (2004).
85. Gil-Dones F, Darde VM, Alonso-Orgaz S et al. Inside human aortic stenosis: a proteomic analysis of plasma. J. Proteomics 75(5), 1639-1653 (2012).
86. Veenstra TD, Conrads TP, Hood BL, Avellino AM, Ellenbogen RG, Morrison RS. Biomarkers: mining the biofluid proteome. Mol. Cell Proteomics 4(4), 409-418 (2005).
87. Fiore CE, Celotta G, Politi GG et al. Association of high α2-Heremans-Schmid glycoprotein/fetuin concentration in serum and intima-media thickness in patients with atherosclerotic vascular disease and low bone mass. Atherosclerosis 195(1), 110-115 (2007).
88. Wang AY, Woo J, Lam CW et al. Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol. Dial. Transplant. 20(8), 1676-1685 (2005).
89. Schafer C, Heiss A, Schwarz A et al. The serum protein α2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J. Clin. Invest. 112(3), 357-366 (2003).
90. Fox PL, Mazumder B, Ehrenwald E, Mukhopadhyay CK. Ceruloplasmin and cardiovascular disease. Free Radic. Biol. Med. 28(12), 1735-1744 (2000).